What's new? Log in Free sign up

Mesoblast Limited (MESO)

Company Profile

Company profile

Ticker

MESO, MEOBF

Exchange

Website

www.mesoblast.com

CEO

Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE ...

Former names

OMNICELL COM /CA/, OMNICELL INC /CA/, OMNICELL, Inc

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

MESO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$13.50

Low target

$12.00

High target

$15.00

Maxim Group

Upgraded

Buy

$12.00

24 Sep 24

Latest filings (excl ownership)

View all

Shelf registration (foreign) (amended)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Shelf registration (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

M&G INVESTMENT MANAGEMENT LTD

Financial summary

Financial statements Chart MESO financial data

Quarter (USD)	Jun 23	Jun 22	Jun 21	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 23	Jun 22	Jun 21	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2024

MESO institutional ownership history Ownership history

20.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	41	24	+70.8%
Opened positions	21	13	+61.5%
Closed positions	4	14	-71.4%
Increased positions	10	1	+900.0%
Reduced positions	2	9	-77.8%

13F shares	Current	Prev Q	Change
Total value	9.65 bn	4.17 bn	+131.6%
Total shares	33.77 mm	33.21 mm	+1.7%
Total puts	130.00 k	28.50 k	+356.1%
Total calls	250.15 k	105.60 k	+136.9%
Total put/call ratio	0.5	0.3	+92.6%

Largest owners	Shares	Value	Change
George Gregory	32.28 mm	$96.69 mm	0.0%
Group One Trading	227.77 k	$1.55 bn	+58.5%
Summit X	147.69 k	$1.01 bn	+5.7%
Penbrook Management	124.93 k	$850.74 mm	-0.2%
Prosperity Wealth Management	90.17 k	$614.02 mm	NEW
MS Morgan Stanley	83.62 k	$569.43 mm	+21.4%
Marshall Wace	82.58 k	$562.34 mm	NEW
Citadel Advisors	77.29 k	$526.37 mm	NEW
Susquehanna International	72.69 k	$495.00 mm	+26.4%
BLK BlackRock	70.23 k	$478.27 mm	+548.2%

Largest transactions	Shares	Bought/sold	Change
VGI Partners	0.00	-117.24 k	EXIT
Prosperity Wealth Management	90.17 k	+90.17 k	NEW
Group One Trading	227.77 k	+84.10 k	+58.5%
Marshall Wace	82.58 k	+82.58 k	NEW
Citadel Advisors	77.29 k	+77.29 k	NEW
BLK BlackRock	70.23 k	+59.40 k	+548.2%
Jane Street	58.14 k	+58.14 k	NEW
HRT Financial	0.00	-57.82 k	EXIT
Lazari Capital Management	53.47 k	+53.47 k	NEW
Rockbridge Investment Management, LCC	49.15 k	+49.15 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Jefferies Downgrades Mesoblast to Hold

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.

US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Thursday's Pre-Market Session

What's Going On With Mesoblast Shares Thursday?

Press releases

From Benzinga Pro

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers, with

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States Food and Drug

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.